Literature DB >> 12869659

Impact of drug transporter studies on drug discovery and development.

Naomi Mizuno1, Takuro Niwa, Yoshihisa Yotsumoto, Yuichi Sugiyama.   

Abstract

Drug transporters are expressed in many tissues such as the intestine, liver, kidney, and brain, and play key roles in drug absorption, distribution, and excretion. The information on the functional characteristics of drug transporters provides important information to allow improvements in drug delivery or drug design by targeting specific transporter proteins. In this article we summarize the significant role played by drug transporters in drug disposition, focusing particularly on their potential use during the drug discovery and development process. The use of transporter function offers the possibility of delivering a drug to the target organ, avoiding distribution to other organs (thereby reducing the chance of toxic side effects), controlling the elimination process, and/or improving oral bioavailability. It is useful to select a lead compound that may or may not interact with transporters, depending on whether such an interaction is desirable. The expression system of transporters is an efficient tool for screening the activity of individual transport processes. The changes in pharmacokinetics due to genetic polymorphisms and drug-drug interactions involving transporters can often have a direct and adverse effect on the therapeutic safety and efficacy of many important drugs. To obtain detailed information about these interindividual differences, the contribution made by transporters to drug absorption, distribution, and excretion needs to be taken into account throughout the drug discovery and development process.

Mesh:

Substances:

Year:  2003        PMID: 12869659     DOI: 10.1124/pr.55.3.1

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  78 in total

1.  Screening of the interaction between xenobiotic transporters and PDZ proteins.

Authors:  Yukio Kato; Kazuhiro Yoshida; Chizuru Watanabe; Yoshimichi Sai; Akira Tsuji
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

Review 2.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

3.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

4.  Equivalence-by-design: targeting in vivo drug delivery profile.

Authors:  Mei-Ling Chen; Vincent H L Lee
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

Review 5.  Active efflux across the blood-brain barrier: role of the solute carrier family.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  NeuroRx       Date:  2005-01

Review 6.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

Review 7.  The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport.

Authors:  David T Thwaites; Catriona M H Anderson
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

8.  Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.

Authors:  Irena Loryan; Vikash Sinha; Claire Mackie; Achiel Van Peer; Wilhelmus Drinkenburg; An Vermeulen; Denise Morrison; Mario Monshouwer; Donald Heald; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

9.  The mechanism of the down-regulation of hepatic transporters in rats with indomethacin-induced intestinal injury.

Authors:  Nobuhiro Fujiyama; Yoshihisa Shitara; Toshiharu Horie
Journal:  Dig Dis Sci       Date:  2013-02-27       Impact factor: 3.199

10.  Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.

Authors:  Yu-hua Li; Hui-chang Bi; Ling Huang; Jing Jin; Guo-ping Zhong; Xu-nian Zhou; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.